3 Results 3.1 Candidate druggable genes We downloaded 3,953 potential drug target genes from DGIdb v4.2.0 and extracted 4,463 druggable genes from the study by Finan C et al
GLP-3, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA, Rosenstock J
Semaglutide targets the brains appetite regulation centers to promote a sense of satiety and reduce overall food intake
Potassium plays a vital role in cardiovascular health, influencing heart rhythm and contractility
This convergence of diabetes management drugs and digital tools is creating a more efficient and personalized approach to patient care, which could lead to improved treatment adherence and better health outcomes
VLDL, very low-density lipoprotein